[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fNm8mqUBr3BIS8rcHJ2jHW_HZjblFaKRCXts6VofC4bg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":70,"rows":77},"Boston Medical Center",[4],317,false,39,17,545996,12,258,[14,17,20,22,25,28,31,33],{"name":15,"count":16},"HIV Infection",10,{"name":18,"count":19},"Depression",9,{"name":21,"count":19},"HIV Infections",{"name":23,"count":24},"Obesity",8,{"name":26,"count":27},"Multiple Myeloma",7,{"name":29,"count":30},"Hypertension",6,{"name":32,"count":30},"Anxiety",{"name":34,"count":30},"Chronic Pain",[36,41,46,51,55,60,65],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04206813","An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen","2026-04-15","Gardasil 9 2 dose regimen",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT03529019","Nutrition in Patient With Critical Limb Ischemia","2026-06","Ensure Surgery Immunonutrition Shake",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05443555","Gabapentin to Reduce Alcohol and Improve Viral Load Suppression","2026-08","Gabapentin",{"nctId":52,"briefTitle":53,"date":49,"intervention":54},"NCT06903975","BoTox Into the Sternocleidomastoid Muscles (SCM)","prabotulinumtoxinA-xvfs",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06636669","Probiotics in the Prevention of Recurrent Prosthetic Joint Infection of the Hip and Knee","2027-06","Probiotic",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05329961","Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old","2028-07","Gardasil9",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT00898235","Collection of Samples and Clinical Data From Patients With Amyloid Diseases","2040-12","clonality analysis",[71,72,73,74,75,76],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[78,105,123,141,164,186,223,245,268,286,308,326,344,373,391,418,447,465,483,512,530,548,566,591,616,643,661,688,706,731,820,846,879,903,930,948,966,984,1016,1034,1052,1070,1088,1106,1132,1171,1201,1225,1251,1269,1294,1318,1343,1361,1385,1414,1432,1450,1468,1491,1514,1532,1556,1579,1602,1620,1645,1663,1690,1708,1732,1757,1781,1799,1823,1846,1870,1894,1920,1938,1964,1987,2014,2040,2058,2076],{"intervention":40,"totalTrials":79,"cells":80},1,{"EARLY_PHASE1":81,"PHASE1":84,"PHASE2":86,"PHASE3":88,"PHASE4":90,"NA":103},{"trials":82,"activeCount":83},[],0,{"trials":85,"activeCount":83},[],{"trials":87,"activeCount":83},[],{"trials":89,"activeCount":83},[],{"trials":91,"activeCount":79,"soonestReadout":39},[92],{"nctId":37,"briefTitle":38,"status":93,"phases":94,"primaryCompletion":39,"completion":95,"start":96,"enrollment":97,"conditions":98,"interventions":100},"ACTIVE_NOT_RECRUITING",[75],"2026-10","2020-12-01",352,[99],"HPV Infection",[40,101,102],"Gardasil 9 3 dose regimen","Gardasil 9 rescue dose",{"trials":104,"activeCount":83},[],{"intervention":101,"totalTrials":79,"cells":106},{"EARLY_PHASE1":107,"PHASE1":109,"PHASE2":111,"PHASE3":113,"PHASE4":115,"NA":121},{"trials":108,"activeCount":83},[],{"trials":110,"activeCount":83},[],{"trials":112,"activeCount":83},[],{"trials":114,"activeCount":83},[],{"trials":116,"activeCount":79,"soonestReadout":39},[117],{"nctId":37,"briefTitle":38,"status":93,"phases":118,"primaryCompletion":39,"completion":95,"start":96,"enrollment":97,"conditions":119,"interventions":120},[75],[99],[40,101,102],{"trials":122,"activeCount":83},[],{"intervention":102,"totalTrials":79,"cells":124},{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":129,"PHASE3":131,"PHASE4":133,"NA":139},{"trials":126,"activeCount":83},[],{"trials":128,"activeCount":83},[],{"trials":130,"activeCount":83},[],{"trials":132,"activeCount":83},[],{"trials":134,"activeCount":79,"soonestReadout":39},[135],{"nctId":37,"briefTitle":38,"status":93,"phases":136,"primaryCompletion":39,"completion":95,"start":96,"enrollment":97,"conditions":137,"interventions":138},[75],[99],[40,101,102],{"trials":140,"activeCount":83},[],{"intervention":59,"totalTrials":79,"cells":142},{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":151,"NA":162},{"trials":144,"activeCount":83},[],{"trials":146,"activeCount":83},[],{"trials":148,"activeCount":83},[],{"trials":150,"activeCount":83},[],{"trials":152,"activeCount":79,"soonestReadout":58},[153],{"nctId":56,"briefTitle":57,"status":154,"phases":155,"primaryCompletion":58,"completion":58,"start":156,"enrollment":157,"conditions":158,"interventions":161},"ENROLLING_BY_INVITATION",[75],"2025-08-15",152,[159,160],"Prosthetic-joint Infection","Dysbiosis",[59],{"trials":163,"activeCount":83},[],{"intervention":54,"totalTrials":79,"cells":165},{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":172,"PHASE4":174,"NA":184},{"trials":167,"activeCount":83},[],{"trials":169,"activeCount":83},[],{"trials":171,"activeCount":83},[],{"trials":173,"activeCount":83},[],{"trials":175,"activeCount":79,"soonestReadout":49},[176],{"nctId":52,"briefTitle":53,"status":177,"phases":178,"primaryCompletion":49,"completion":49,"start":179,"enrollment":180,"conditions":181,"interventions":183},"RECRUITING",[75],"2025-05-14",30,[182],"Neck Muscle Issue",[54],{"trials":185,"activeCount":83},[],{"intervention":50,"totalTrials":187,"cells":188},2,{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":217,"PHASE4":219,"NA":221},{"trials":190,"activeCount":83},[],{"trials":192,"activeCount":83},[],{"trials":194,"activeCount":79,"soonestReadout":49},[195,208],{"nctId":196,"briefTitle":197,"status":198,"phases":199,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":206},"NCT04052139","St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Gabapentin","COMPLETED",[73],"2021-11-16","2021-12-15","2021-01-25",45,[34,205,21],"Alcohol Use, Unspecified",[207,50],"Low-dose naltrexone",{"nctId":47,"briefTitle":48,"status":177,"phases":209,"primaryCompletion":49,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":216},[73],"2027-05","2023-11-20",220,[214,215],"HIV","Heavy Drinking",[50],{"trials":218,"activeCount":83},[],{"trials":220,"activeCount":83},[],{"trials":222,"activeCount":83},[],{"intervention":64,"totalTrials":79,"cells":224},{"EARLY_PHASE1":225,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":241,"NA":243},{"trials":226,"activeCount":79,"soonestReadout":63},[227],{"nctId":61,"briefTitle":62,"status":93,"phases":228,"primaryCompletion":63,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":234},[71],"2028-12","2022-09-26",155,[233],"Human Papilloma Virus",[64],{"trials":236,"activeCount":83},[],{"trials":238,"activeCount":83},[],{"trials":240,"activeCount":83},[],{"trials":242,"activeCount":83},[],{"trials":244,"activeCount":83},[],{"intervention":45,"totalTrials":79,"cells":246},{"EARLY_PHASE1":247,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":264,"NA":266},{"trials":248,"activeCount":79,"soonestReadout":44},[249],{"nctId":42,"briefTitle":43,"status":177,"phases":250,"primaryCompletion":44,"completion":44,"start":251,"enrollment":180,"conditions":252,"interventions":256},[71],"2018-10-02",[253,254,255],"Critical Limb Ischemia","Malnutrition","Nutritional Supplements",[45,257],"Ensure Enlive Advanced Nutrition Shake",{"trials":259,"activeCount":83},[],{"trials":261,"activeCount":83},[],{"trials":263,"activeCount":83},[],{"trials":265,"activeCount":83},[],{"trials":267,"activeCount":83},[],{"intervention":257,"totalTrials":79,"cells":269},{"EARLY_PHASE1":270,"PHASE1":276,"PHASE2":278,"PHASE3":280,"PHASE4":282,"NA":284},{"trials":271,"activeCount":79,"soonestReadout":44},[272],{"nctId":42,"briefTitle":43,"status":177,"phases":273,"primaryCompletion":44,"completion":44,"start":251,"enrollment":180,"conditions":274,"interventions":275},[71],[253,254,255],[45,257],{"trials":277,"activeCount":83},[],{"trials":279,"activeCount":83},[],{"trials":281,"activeCount":83},[],{"trials":283,"activeCount":83},[],{"trials":285,"activeCount":83},[],{"intervention":69,"totalTrials":79,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":296,"NA":298},{"trials":289,"activeCount":83},[],{"trials":291,"activeCount":83},[],{"trials":293,"activeCount":83},[],{"trials":295,"activeCount":83},[],{"trials":297,"activeCount":83},[],{"trials":299,"activeCount":79,"soonestReadout":68},[300],{"nctId":66,"briefTitle":67,"status":177,"phases":301,"primaryCompletion":68,"completion":68,"start":302,"enrollment":303,"conditions":304,"interventions":305},[],"2000-01",10000,[26],[69,306,307],"polymerase chain reaction","protein analysis",{"intervention":306,"totalTrials":79,"cells":309},{"EARLY_PHASE1":310,"PHASE1":312,"PHASE2":314,"PHASE3":316,"PHASE4":318,"NA":320},{"trials":311,"activeCount":83},[],{"trials":313,"activeCount":83},[],{"trials":315,"activeCount":83},[],{"trials":317,"activeCount":83},[],{"trials":319,"activeCount":83},[],{"trials":321,"activeCount":79,"soonestReadout":68},[322],{"nctId":66,"briefTitle":67,"status":177,"phases":323,"primaryCompletion":68,"completion":68,"start":302,"enrollment":303,"conditions":324,"interventions":325},[],[26],[69,306,307],{"intervention":307,"totalTrials":79,"cells":327},{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":336,"NA":338},{"trials":329,"activeCount":83},[],{"trials":331,"activeCount":83},[],{"trials":333,"activeCount":83},[],{"trials":335,"activeCount":83},[],{"trials":337,"activeCount":83},[],{"trials":339,"activeCount":79,"soonestReadout":68},[340],{"nctId":66,"briefTitle":67,"status":177,"phases":341,"primaryCompletion":68,"completion":68,"start":302,"enrollment":303,"conditions":342,"interventions":343},[],[26],[69,306,307],{"intervention":345,"totalTrials":79,"cells":346},"Topical testosterone gel 1%",{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":353,"PHASE4":355,"NA":371},{"trials":348,"activeCount":83},[],{"trials":350,"activeCount":83},[],{"trials":352,"activeCount":83},[],{"trials":354,"activeCount":83},[],{"trials":356,"activeCount":83},[357],{"nctId":358,"briefTitle":359,"status":360,"phases":361,"primaryCompletion":362,"completion":362,"start":363,"enrollment":364,"conditions":365,"interventions":369},"NCT00240981","TOM: Testosterone in Older Men With Sarcopenia","TERMINATED",[75],"2009-12","2005-01",209,[366,367,368],"Sarcopenia","Hypogonadism","Muscular Diseases",[345,370],"Topical gel",{"trials":372,"activeCount":83},[],{"intervention":370,"totalTrials":79,"cells":374},{"EARLY_PHASE1":375,"PHASE1":377,"PHASE2":379,"PHASE3":381,"PHASE4":383,"NA":389},{"trials":376,"activeCount":83},[],{"trials":378,"activeCount":83},[],{"trials":380,"activeCount":83},[],{"trials":382,"activeCount":83},[],{"trials":384,"activeCount":83},[385],{"nctId":358,"briefTitle":359,"status":360,"phases":386,"primaryCompletion":362,"completion":362,"start":363,"enrollment":364,"conditions":387,"interventions":388},[75],[366,367,368],[345,370],{"trials":390,"activeCount":83},[],{"intervention":392,"totalTrials":79,"cells":393},"Quetiapine",{"EARLY_PHASE1":394,"PHASE1":396,"PHASE2":398,"PHASE3":400,"PHASE4":402,"NA":416},{"trials":395,"activeCount":83},[],{"trials":397,"activeCount":83},[],{"trials":399,"activeCount":83},[],{"trials":401,"activeCount":83},[],{"trials":403,"activeCount":83},[404],{"nctId":405,"briefTitle":406,"status":198,"phases":407,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":415},"NCT02845453","Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation",[75],"2021-04-07","2017-01-20",24,[412,413,414],"Substance Use Disorders","Bipolar Disorder","Mood Disorders",[392],{"trials":417,"activeCount":83},[],{"intervention":419,"totalTrials":79,"cells":420},"Dexmedetomidine",{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":427,"PHASE4":429,"NA":445},{"trials":422,"activeCount":83},[],{"trials":424,"activeCount":83},[],{"trials":426,"activeCount":83},[],{"trials":428,"activeCount":83},[],{"trials":430,"activeCount":83},[431],{"nctId":432,"briefTitle":433,"status":198,"phases":434,"primaryCompletion":435,"completion":436,"start":437,"enrollment":438,"conditions":439,"interventions":442},"NCT06093893","Hypotensive Anesthesia for Orthognathic Surgery",[75],"2026-01-07","2026-02-06","2025-03-04",90,[440,441],"Hypotensive Anesthesia","Orthognathic Surgery",[419,443,444],"Nicardipine","Labetalol",{"trials":446,"activeCount":83},[],{"intervention":443,"totalTrials":79,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":455,"PHASE4":457,"NA":463},{"trials":450,"activeCount":83},[],{"trials":452,"activeCount":83},[],{"trials":454,"activeCount":83},[],{"trials":456,"activeCount":83},[],{"trials":458,"activeCount":83},[459],{"nctId":432,"briefTitle":433,"status":198,"phases":460,"primaryCompletion":435,"completion":436,"start":437,"enrollment":438,"conditions":461,"interventions":462},[75],[440,441],[419,443,444],{"trials":464,"activeCount":83},[],{"intervention":444,"totalTrials":79,"cells":466},{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":475,"NA":481},{"trials":468,"activeCount":83},[],{"trials":470,"activeCount":83},[],{"trials":472,"activeCount":83},[],{"trials":474,"activeCount":83},[],{"trials":476,"activeCount":83},[477],{"nctId":432,"briefTitle":433,"status":198,"phases":478,"primaryCompletion":435,"completion":436,"start":437,"enrollment":438,"conditions":479,"interventions":480},[75],[440,441],[419,443,444],{"trials":482,"activeCount":83},[],{"intervention":484,"totalTrials":79,"cells":485},"Triazolam",{"EARLY_PHASE1":486,"PHASE1":488,"PHASE2":490,"PHASE3":492,"PHASE4":494,"NA":510},{"trials":487,"activeCount":83},[],{"trials":489,"activeCount":83},[],{"trials":491,"activeCount":83},[],{"trials":493,"activeCount":83},[],{"trials":495,"activeCount":83},[496],{"nctId":497,"briefTitle":498,"status":198,"phases":499,"primaryCompletion":500,"completion":500,"start":501,"enrollment":502,"conditions":503,"interventions":506},"NCT03246724","Oral Versus Intravenous Sedation for Ocular Procedures",[75],"2019-11-30","2017-10-16",327,[504,505],"Surgery","Sedation",[484,507,508,509],"Midazolam","Microcrystalline Cellulose","Sodium chloride 0.9%",{"trials":511,"activeCount":83},[],{"intervention":507,"totalTrials":79,"cells":513},{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":520,"PHASE4":522,"NA":528},{"trials":515,"activeCount":83},[],{"trials":517,"activeCount":83},[],{"trials":519,"activeCount":83},[],{"trials":521,"activeCount":83},[],{"trials":523,"activeCount":83},[524],{"nctId":497,"briefTitle":498,"status":198,"phases":525,"primaryCompletion":500,"completion":500,"start":501,"enrollment":502,"conditions":526,"interventions":527},[75],[504,505],[484,507,508,509],{"trials":529,"activeCount":83},[],{"intervention":508,"totalTrials":79,"cells":531},{"EARLY_PHASE1":532,"PHASE1":534,"PHASE2":536,"PHASE3":538,"PHASE4":540,"NA":546},{"trials":533,"activeCount":83},[],{"trials":535,"activeCount":83},[],{"trials":537,"activeCount":83},[],{"trials":539,"activeCount":83},[],{"trials":541,"activeCount":83},[542],{"nctId":497,"briefTitle":498,"status":198,"phases":543,"primaryCompletion":500,"completion":500,"start":501,"enrollment":502,"conditions":544,"interventions":545},[75],[504,505],[484,507,508,509],{"trials":547,"activeCount":83},[],{"intervention":509,"totalTrials":79,"cells":549},{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":556,"PHASE4":558,"NA":564},{"trials":551,"activeCount":83},[],{"trials":553,"activeCount":83},[],{"trials":555,"activeCount":83},[],{"trials":557,"activeCount":83},[],{"trials":559,"activeCount":83},[560],{"nctId":497,"briefTitle":498,"status":198,"phases":561,"primaryCompletion":500,"completion":500,"start":501,"enrollment":502,"conditions":562,"interventions":563},[75],[504,505],[484,507,508,509],{"trials":565,"activeCount":83},[],{"intervention":567,"totalTrials":79,"cells":568},"SHINGRIX",{"EARLY_PHASE1":569,"PHASE1":571,"PHASE2":573,"PHASE3":575,"PHASE4":577,"NA":589},{"trials":570,"activeCount":83},[],{"trials":572,"activeCount":83},[],{"trials":574,"activeCount":83},[],{"trials":576,"activeCount":83},[],{"trials":578,"activeCount":83},[579],{"nctId":580,"briefTitle":581,"status":360,"phases":582,"primaryCompletion":583,"completion":583,"start":584,"enrollment":585,"conditions":586,"interventions":588},"NCT03591770","Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib",[75],"2024-07-04","2019-07-31",15,[587],"Inflammatory Bowel Diseases",[567],{"trials":590,"activeCount":83},[],{"intervention":592,"totalTrials":79,"cells":593},"Pharmacotherapy for opioid use disorder",{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":600,"PHASE4":602,"NA":614},{"trials":595,"activeCount":83},[],{"trials":597,"activeCount":83},[],{"trials":599,"activeCount":83},[],{"trials":601,"activeCount":83},[],{"trials":603,"activeCount":83},[604],{"nctId":605,"briefTitle":606,"status":198,"phases":607,"primaryCompletion":608,"completion":608,"start":609,"enrollment":610,"conditions":611,"interventions":613},"NCT03290391","Linking Infectious and Narcology Care-Part II",[75],"2022-04-06","2018-09-19",225,[15,612],"Drug Use",[592],{"trials":615,"activeCount":83},[],{"intervention":617,"totalTrials":79,"cells":618},"Otiprio",{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":627,"NA":641},{"trials":620,"activeCount":83},[],{"trials":622,"activeCount":83},[],{"trials":624,"activeCount":83},[],{"trials":626,"activeCount":83},[],{"trials":628,"activeCount":83},[629],{"nctId":630,"briefTitle":631,"status":632,"phases":633,"primaryCompletion":634,"completion":634,"start":635,"enrollment":83,"conditions":636,"interventions":639},"NCT03347461","Otiprio Versus Ciprodex Tympanostomy Tube Outcomes","WITHDRAWN",[75],"2019-06","2018-10",[637,638],"Otorrhea","Otitis Media With Effusion in Children",[617,640],"Ciprodex",{"trials":642,"activeCount":83},[],{"intervention":640,"totalTrials":79,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":653,"NA":659},{"trials":646,"activeCount":83},[],{"trials":648,"activeCount":83},[],{"trials":650,"activeCount":83},[],{"trials":652,"activeCount":83},[],{"trials":654,"activeCount":83},[655],{"nctId":630,"briefTitle":631,"status":632,"phases":656,"primaryCompletion":634,"completion":634,"start":635,"enrollment":83,"conditions":657,"interventions":658},[75],[637,638],[617,640],{"trials":660,"activeCount":83},[],{"intervention":662,"totalTrials":79,"cells":663},"Methadone Pill",{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":670,"PHASE4":672,"NA":686},{"trials":665,"activeCount":83},[],{"trials":667,"activeCount":83},[],{"trials":669,"activeCount":83},[],{"trials":671,"activeCount":83},[],{"trials":673,"activeCount":83},[674],{"nctId":675,"briefTitle":676,"status":360,"phases":677,"primaryCompletion":678,"completion":678,"start":679,"enrollment":680,"conditions":681,"interventions":684},"NCT04941443","Methadone and Medication Abortion",[75],"2022-03-01","2021-10-04",4,[682,683],"Pain","Medical Abortion",[662,685],"Ibuprofen",{"trials":687,"activeCount":83},[],{"intervention":685,"totalTrials":79,"cells":689},{"EARLY_PHASE1":690,"PHASE1":692,"PHASE2":694,"PHASE3":696,"PHASE4":698,"NA":704},{"trials":691,"activeCount":83},[],{"trials":693,"activeCount":83},[],{"trials":695,"activeCount":83},[],{"trials":697,"activeCount":83},[],{"trials":699,"activeCount":83},[700],{"nctId":675,"briefTitle":676,"status":360,"phases":701,"primaryCompletion":678,"completion":678,"start":679,"enrollment":680,"conditions":702,"interventions":703},[75],[682,683],[662,685],{"trials":705,"activeCount":83},[],{"intervention":707,"totalTrials":79,"cells":708},"Duloxetine",{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":713,"PHASE3":715,"PHASE4":717,"NA":729},{"trials":710,"activeCount":83},[],{"trials":712,"activeCount":83},[],{"trials":714,"activeCount":83},[],{"trials":716,"activeCount":83},[],{"trials":718,"activeCount":83},[719],{"nctId":720,"briefTitle":721,"status":632,"phases":722,"primaryCompletion":723,"completion":723,"start":724,"enrollment":83,"conditions":725,"interventions":728},"NCT04639011","Duloxetine Tibial Plateau",[75],"2023-12","2022-10",[726,727],"Tibial Plateau Fracture","Pain, Postoperative",[707],{"trials":730,"activeCount":83},[],{"intervention":732,"totalTrials":27,"cells":733},"melphalan",{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":803,"PHASE4":816,"NA":818},{"trials":735,"activeCount":83},[],{"trials":737,"activeCount":83},[],{"trials":739,"activeCount":83},[740,751,760,771,780,790],{"nctId":741,"briefTitle":742,"status":198,"phases":743,"primaryCompletion":744,"completion":745,"start":746,"enrollment":16,"conditions":747,"interventions":748},"NCT00790647","Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis",[73],"2012-12","2014-11","2008-06",[26],[749,750,732],"filgrastim","bortezomib",{"nctId":752,"briefTitle":753,"status":360,"phases":754,"primaryCompletion":755,"completion":755,"start":756,"enrollment":11,"conditions":757,"interventions":759},"NCT00075608","2nd Autologous Stem Cell Transplant in Patients With Persistent\u002FRecurrent (AL) Amyloidosis",[73],"2011-10","2001-08",[26,758],"Plasma Cell Neoplasm",[749,732],{"nctId":761,"briefTitle":762,"status":198,"phases":763,"primaryCompletion":764,"completion":764,"start":765,"enrollment":766,"conditions":767,"interventions":768},"NCT00679367","Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis",[73],"2015-05","2008-05",16,[26],[769,770,732],"dexamethasone","lenalidomide",{"nctId":772,"briefTitle":773,"status":360,"phases":774,"primaryCompletion":775,"completion":775,"start":776,"enrollment":777,"conditions":778,"interventions":779},"NCT00681044","HD Melphalan and SCT in Patients With IGDD or LCDD",[73],"2016-01","2006-10",5,[26],[749,732],{"nctId":781,"briefTitle":782,"status":198,"phases":783,"primaryCompletion":784,"completion":785,"start":786,"enrollment":787,"conditions":788,"interventions":789},"NCT00075621","Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis",[73],"2005-06","2020-09-04","2000-08",62,[26],[749,732],{"nctId":791,"briefTitle":792,"status":198,"phases":793,"primaryCompletion":794,"completion":785,"start":795,"enrollment":796,"conditions":797,"interventions":799},"NCT01083316","Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis",[73],"2013-08","2009-09",35,[798],"Amyloidosis",[800,801,802],"Bortezomib","Dexamethasone","Melphalan",{"trials":804,"activeCount":83},[805],{"nctId":806,"briefTitle":807,"status":360,"phases":808,"primaryCompletion":809,"completion":809,"start":810,"enrollment":811,"conditions":812,"interventions":814},"NCT02489500","Trial of High Dose Melphalan\u002FStem Cell Transplant With or Without Bortezomib",[74],"2017-04-28","2015-06",3,[813],"AL Amyloidosis",[800,802,815],"Neupogen",{"trials":817,"activeCount":83},[],{"trials":819,"activeCount":83},[],{"intervention":800,"totalTrials":811,"cells":821},{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":836,"PHASE4":842,"NA":844},{"trials":823,"activeCount":83},[],{"trials":825,"activeCount":83},[],{"trials":827,"activeCount":83},[828,832],{"nctId":741,"briefTitle":742,"status":198,"phases":829,"primaryCompletion":744,"completion":745,"start":746,"enrollment":16,"conditions":830,"interventions":831},[73],[26],[749,750,732],{"nctId":791,"briefTitle":792,"status":198,"phases":833,"primaryCompletion":794,"completion":785,"start":795,"enrollment":796,"conditions":834,"interventions":835},[73],[798],[800,801,802],{"trials":837,"activeCount":83},[838],{"nctId":806,"briefTitle":807,"status":360,"phases":839,"primaryCompletion":809,"completion":809,"start":810,"enrollment":811,"conditions":840,"interventions":841},[74],[813],[800,802,815],{"trials":843,"activeCount":83},[],{"trials":845,"activeCount":83},[],{"intervention":847,"totalTrials":187,"cells":848},"Amitriptyline",{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":855,"PHASE4":875,"NA":877},{"trials":850,"activeCount":83},[],{"trials":852,"activeCount":83},[],{"trials":854,"activeCount":83},[],{"trials":856,"activeCount":83},[857,866],{"nctId":858,"briefTitle":859,"status":360,"phases":860,"primaryCompletion":861,"completion":861,"start":862,"enrollment":30,"conditions":863,"interventions":865},"NCT02552225","Treatment of Chronic Laryngitis With Amitriptyline",[73,74],"2021-01-15","2016-04",[864],"Laryngeal Diseases",[847],{"nctId":867,"briefTitle":868,"status":360,"phases":869,"primaryCompletion":870,"completion":870,"start":871,"enrollment":180,"conditions":872,"interventions":874},"NCT02434523","Trial of the Treatment of Chronic Laryngitis With Amitryptiline",[73,74],"2015-01","2013-09",[864,873],"Chronic Laryngeal Neuropathy",[847],{"trials":876,"activeCount":83},[],{"trials":878,"activeCount":83},[],{"intervention":880,"totalTrials":79,"cells":881},"Probiotic oral lozenges",{"EARLY_PHASE1":882,"PHASE1":884,"PHASE2":886,"PHASE3":888,"PHASE4":899,"NA":901},{"trials":883,"activeCount":83},[],{"trials":885,"activeCount":83},[],{"trials":887,"activeCount":83},[],{"trials":889,"activeCount":83},[890],{"nctId":891,"briefTitle":892,"status":632,"phases":893,"primaryCompletion":894,"completion":894,"start":895,"enrollment":83,"conditions":896,"interventions":898},"NCT05707702","Lactobacillus Lozenges as Preventative Care in Low-grade Dysplasia",[74],"2025-11","2024-04-29",[897],"Low-grade Oral Dysplasia",[880],{"trials":900,"activeCount":83},[],{"trials":902,"activeCount":83},[],{"intervention":904,"totalTrials":79,"cells":905},"Insulin glargine",{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":926,"NA":928},{"trials":907,"activeCount":83},[],{"trials":909,"activeCount":83},[],{"trials":911,"activeCount":83},[],{"trials":913,"activeCount":83},[914],{"nctId":915,"briefTitle":916,"status":198,"phases":917,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":921,"interventions":923},"NCT04460326","Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus",[74],"2023-05-27","2020-12-07",137,[922],"Type 2 Diabetes Treated With Insulin",[904,924,925],"NovoLog","Insulin Fiasp",{"trials":927,"activeCount":83},[],{"trials":929,"activeCount":83},[],{"intervention":924,"totalTrials":79,"cells":931},{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":938,"PHASE4":944,"NA":946},{"trials":933,"activeCount":83},[],{"trials":935,"activeCount":83},[],{"trials":937,"activeCount":83},[],{"trials":939,"activeCount":83},[940],{"nctId":915,"briefTitle":916,"status":198,"phases":941,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":942,"interventions":943},[74],[922],[904,924,925],{"trials":945,"activeCount":83},[],{"trials":947,"activeCount":83},[],{"intervention":925,"totalTrials":79,"cells":949},{"EARLY_PHASE1":950,"PHASE1":952,"PHASE2":954,"PHASE3":956,"PHASE4":962,"NA":964},{"trials":951,"activeCount":83},[],{"trials":953,"activeCount":83},[],{"trials":955,"activeCount":83},[],{"trials":957,"activeCount":83},[958],{"nctId":915,"briefTitle":916,"status":198,"phases":959,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":960,"interventions":961},[74],[922],[904,924,925],{"trials":963,"activeCount":83},[],{"trials":965,"activeCount":83},[],{"intervention":815,"totalTrials":79,"cells":967},{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":974,"PHASE4":980,"NA":982},{"trials":969,"activeCount":83},[],{"trials":971,"activeCount":83},[],{"trials":973,"activeCount":83},[],{"trials":975,"activeCount":83},[976],{"nctId":806,"briefTitle":807,"status":360,"phases":977,"primaryCompletion":809,"completion":809,"start":810,"enrollment":811,"conditions":978,"interventions":979},[74],[813],[800,802,815],{"trials":981,"activeCount":83},[],{"trials":983,"activeCount":83},[],{"intervention":985,"totalTrials":79,"cells":986},"Varenicline",{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":993,"PHASE4":1012,"NA":1014},{"trials":988,"activeCount":83},[],{"trials":990,"activeCount":83},[],{"trials":992,"activeCount":83},[],{"trials":994,"activeCount":83},[995],{"nctId":996,"briefTitle":997,"status":198,"phases":998,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":1003,"interventions":1006},"NCT02797587","Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians With HIV (St PETER HIV)",[73,74],"2020-04-30","2020-12-15","2017-07-19",400,[15,1004,1005],"Alcohol Use","Smoking",[985,1007,1008,1009,1010,1011],"Cytisine","Nicotine Replacement Therapy","Varenicline Placebo","Cytisine Placebo","Nicotine Replacement Therapy Placebo",{"trials":1013,"activeCount":83},[],{"trials":1015,"activeCount":83},[],{"intervention":1007,"totalTrials":79,"cells":1017},{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1024,"PHASE4":1030,"NA":1032},{"trials":1019,"activeCount":83},[],{"trials":1021,"activeCount":83},[],{"trials":1023,"activeCount":83},[],{"trials":1025,"activeCount":83},[1026],{"nctId":996,"briefTitle":997,"status":198,"phases":1027,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":1028,"interventions":1029},[73,74],[15,1004,1005],[985,1007,1008,1009,1010,1011],{"trials":1031,"activeCount":83},[],{"trials":1033,"activeCount":83},[],{"intervention":1008,"totalTrials":79,"cells":1035},{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1040,"PHASE3":1042,"PHASE4":1048,"NA":1050},{"trials":1037,"activeCount":83},[],{"trials":1039,"activeCount":83},[],{"trials":1041,"activeCount":83},[],{"trials":1043,"activeCount":83},[1044],{"nctId":996,"briefTitle":997,"status":198,"phases":1045,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":1046,"interventions":1047},[73,74],[15,1004,1005],[985,1007,1008,1009,1010,1011],{"trials":1049,"activeCount":83},[],{"trials":1051,"activeCount":83},[],{"intervention":1009,"totalTrials":79,"cells":1053},{"EARLY_PHASE1":1054,"PHASE1":1056,"PHASE2":1058,"PHASE3":1060,"PHASE4":1066,"NA":1068},{"trials":1055,"activeCount":83},[],{"trials":1057,"activeCount":83},[],{"trials":1059,"activeCount":83},[],{"trials":1061,"activeCount":83},[1062],{"nctId":996,"briefTitle":997,"status":198,"phases":1063,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":1064,"interventions":1065},[73,74],[15,1004,1005],[985,1007,1008,1009,1010,1011],{"trials":1067,"activeCount":83},[],{"trials":1069,"activeCount":83},[],{"intervention":1010,"totalTrials":79,"cells":1071},{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1078,"PHASE4":1084,"NA":1086},{"trials":1073,"activeCount":83},[],{"trials":1075,"activeCount":83},[],{"trials":1077,"activeCount":83},[],{"trials":1079,"activeCount":83},[1080],{"nctId":996,"briefTitle":997,"status":198,"phases":1081,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":1082,"interventions":1083},[73,74],[15,1004,1005],[985,1007,1008,1009,1010,1011],{"trials":1085,"activeCount":83},[],{"trials":1087,"activeCount":83},[],{"intervention":1011,"totalTrials":79,"cells":1089},{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1094,"PHASE3":1096,"PHASE4":1102,"NA":1104},{"trials":1091,"activeCount":83},[],{"trials":1093,"activeCount":83},[],{"trials":1095,"activeCount":83},[],{"trials":1097,"activeCount":83},[1098],{"nctId":996,"briefTitle":997,"status":198,"phases":1099,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":1100,"interventions":1101},[73,74],[15,1004,1005],[985,1007,1008,1009,1010,1011],{"trials":1103,"activeCount":83},[],{"trials":1105,"activeCount":83},[],{"intervention":1107,"totalTrials":79,"cells":1108},"Venlafaxine",{"EARLY_PHASE1":1109,"PHASE1":1111,"PHASE2":1113,"PHASE3":1115,"PHASE4":1128,"NA":1130},{"trials":1110,"activeCount":83},[],{"trials":1112,"activeCount":83},[],{"trials":1114,"activeCount":83},[],{"trials":1116,"activeCount":83},[1117],{"nctId":1118,"briefTitle":1119,"status":198,"phases":1120,"primaryCompletion":1121,"completion":1121,"start":1122,"enrollment":1123,"conditions":1124,"interventions":1127},"NCT00248612","Psychosocial and Medication Treatment for Anxiety in Alcoholism",[73,74],"2009-03","2003-09",162,[1125,1126],"Alcohol-Related Disorders","Anxiety Disorders",[1107],{"trials":1129,"activeCount":83},[],{"trials":1131,"activeCount":83},[],{"intervention":801,"totalTrials":680,"cells":1133},{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1165,"PHASE4":1167,"NA":1169},{"trials":1135,"activeCount":83},[],{"trials":1137,"activeCount":83},[],{"trials":1139,"activeCount":83},[1140,1146,1150,1161],{"nctId":1141,"briefTitle":1142,"status":632,"phases":1143,"primaryCompletion":862,"completion":862,"start":764,"enrollment":83,"conditions":1144,"interventions":1145},"NCT02402725","A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma",[73],[26],[801],{"nctId":761,"briefTitle":762,"status":198,"phases":1147,"primaryCompletion":764,"completion":764,"start":765,"enrollment":766,"conditions":1148,"interventions":1149},[73],[26],[769,770,732],{"nctId":1151,"briefTitle":1152,"status":198,"phases":1153,"primaryCompletion":1154,"completion":1155,"start":1156,"enrollment":1157,"conditions":1158,"interventions":1159},"NCT01570387","A Phase I\u002FII Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis",[72,73],"2018-11","2019-04","2012-06",27,[813],[1160,801],"Pomalidomide",{"nctId":791,"briefTitle":792,"status":198,"phases":1162,"primaryCompletion":794,"completion":785,"start":795,"enrollment":796,"conditions":1163,"interventions":1164},[73],[798],[800,801,802],{"trials":1166,"activeCount":83},[],{"trials":1168,"activeCount":83},[],{"trials":1170,"activeCount":83},[],{"intervention":749,"totalTrials":680,"cells":1172},{"EARLY_PHASE1":1173,"PHASE1":1175,"PHASE2":1177,"PHASE3":1195,"PHASE4":1197,"NA":1199},{"trials":1174,"activeCount":83},[],{"trials":1176,"activeCount":83},[],{"trials":1178,"activeCount":83},[1179,1183,1187,1191],{"nctId":741,"briefTitle":742,"status":198,"phases":1180,"primaryCompletion":744,"completion":745,"start":746,"enrollment":16,"conditions":1181,"interventions":1182},[73],[26],[749,750,732],{"nctId":752,"briefTitle":753,"status":360,"phases":1184,"primaryCompletion":755,"completion":755,"start":756,"enrollment":11,"conditions":1185,"interventions":1186},[73],[26,758],[749,732],{"nctId":772,"briefTitle":773,"status":360,"phases":1188,"primaryCompletion":775,"completion":775,"start":776,"enrollment":777,"conditions":1189,"interventions":1190},[73],[26],[749,732],{"nctId":781,"briefTitle":782,"status":198,"phases":1192,"primaryCompletion":784,"completion":785,"start":786,"enrollment":787,"conditions":1193,"interventions":1194},[73],[26],[749,732],{"trials":1196,"activeCount":83},[],{"trials":1198,"activeCount":83},[],{"trials":1200,"activeCount":83},[],{"intervention":1202,"totalTrials":79,"cells":1203},"CC-1088",{"EARLY_PHASE1":1204,"PHASE1":1206,"PHASE2":1208,"PHASE3":1219,"PHASE4":1221,"NA":1223},{"trials":1205,"activeCount":83},[],{"trials":1207,"activeCount":83},[],{"trials":1209,"activeCount":83},[1210],{"nctId":1211,"briefTitle":1212,"status":198,"phases":1213,"primaryCompletion":1214,"completion":1214,"start":1215,"conditions":1216,"interventions":1218},"NCT00006097","Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia",[72,73],"2005-07","1999-08",[1217],"Leukemia",[1202],{"trials":1220,"activeCount":83},[],{"trials":1222,"activeCount":83},[],{"trials":1224,"activeCount":83},[],{"intervention":1226,"totalTrials":79,"cells":1227},"Nefazodone",{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1245,"PHASE4":1247,"NA":1249},{"trials":1229,"activeCount":83},[],{"trials":1231,"activeCount":83},[],{"trials":1233,"activeCount":83},[1234],{"nctId":1235,"briefTitle":1236,"status":198,"phases":1237,"primaryCompletion":1238,"start":1239,"enrollment":1240,"conditions":1241,"interventions":1244},"NCT00015210","Nefazodone in the Treatment of Cocaine Dependence and Depression - 4",[73],"1999-05","1997-02",69,[1242,1243],"Cocaine-Related Disorders","Substance-Related Disorders",[1226],{"trials":1246,"activeCount":83},[],{"trials":1248,"activeCount":83},[],{"trials":1250,"activeCount":83},[],{"intervention":207,"totalTrials":79,"cells":1252},{"EARLY_PHASE1":1253,"PHASE1":1255,"PHASE2":1257,"PHASE3":1263,"PHASE4":1265,"NA":1267},{"trials":1254,"activeCount":83},[],{"trials":1256,"activeCount":83},[],{"trials":1258,"activeCount":83},[1259],{"nctId":196,"briefTitle":197,"status":198,"phases":1260,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":1261,"interventions":1262},[73],[34,205,21],[207,50],{"trials":1264,"activeCount":83},[],{"trials":1266,"activeCount":83},[],{"trials":1268,"activeCount":83},[],{"intervention":1270,"totalTrials":79,"cells":1271},"daratumumab",{"EARLY_PHASE1":1272,"PHASE1":1274,"PHASE2":1276,"PHASE3":1288,"PHASE4":1290,"NA":1292},{"trials":1273,"activeCount":83},[],{"trials":1275,"activeCount":83},[],{"trials":1277,"activeCount":83},[1278],{"nctId":1279,"briefTitle":1280,"status":198,"phases":1281,"primaryCompletion":1282,"completion":1283,"start":1284,"enrollment":1285,"conditions":1286,"interventions":1287},"NCT02841033","Daratumumab for the Treatment of Patients With AL Amyloidosis",[72,73],"2020-05-28","2020-07-17","2017-03-20",22,[813],[1270],{"trials":1289,"activeCount":83},[],{"trials":1291,"activeCount":83},[],{"trials":1293,"activeCount":83},[],{"intervention":1295,"totalTrials":79,"cells":1296},"Fecal Microbiota Transplant",{"EARLY_PHASE1":1297,"PHASE1":1299,"PHASE2":1301,"PHASE3":1312,"PHASE4":1314,"NA":1316},{"trials":1298,"activeCount":83},[],{"trials":1300,"activeCount":83},[],{"trials":1302,"activeCount":83},[1303],{"nctId":1304,"briefTitle":1305,"status":360,"phases":1306,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":410,"conditions":1309,"interventions":1311},"NCT02417974","Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)",[73],"2021-02-04","2015-09",[1310],"Crohn's Disease",[1295],{"trials":1313,"activeCount":83},[],{"trials":1315,"activeCount":83},[],{"trials":1317,"activeCount":83},[],{"intervention":1319,"totalTrials":79,"cells":1320},"Low dose naltrexone",{"EARLY_PHASE1":1321,"PHASE1":1323,"PHASE2":1325,"PHASE3":1337,"PHASE4":1339,"NA":1341},{"trials":1322,"activeCount":83},[],{"trials":1324,"activeCount":83},[],{"trials":1326,"activeCount":83},[1327],{"nctId":1328,"briefTitle":1329,"status":198,"phases":1330,"primaryCompletion":1331,"completion":1331,"start":1332,"enrollment":1333,"conditions":1334,"interventions":1335},"NCT03278886","St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene",[72,73],"2018-12-19","2018-07-03",11,[15,1004,682],[1319,1336],"Nalmefene",{"trials":1338,"activeCount":83},[],{"trials":1340,"activeCount":83},[],{"trials":1342,"activeCount":83},[],{"intervention":1336,"totalTrials":79,"cells":1344},{"EARLY_PHASE1":1345,"PHASE1":1347,"PHASE2":1349,"PHASE3":1355,"PHASE4":1357,"NA":1359},{"trials":1346,"activeCount":83},[],{"trials":1348,"activeCount":83},[],{"trials":1350,"activeCount":83},[1351],{"nctId":1328,"briefTitle":1329,"status":198,"phases":1352,"primaryCompletion":1331,"completion":1331,"start":1332,"enrollment":1333,"conditions":1353,"interventions":1354},[72,73],[15,1004,682],[1319,1336],{"trials":1356,"activeCount":83},[],{"trials":1358,"activeCount":83},[],{"trials":1360,"activeCount":83},[],{"intervention":1362,"totalTrials":79,"cells":1363},"Propylene Glycol-Free Melphalan Hydrochloride",{"EARLY_PHASE1":1364,"PHASE1":1366,"PHASE2":1368,"PHASE3":1379,"PHASE4":1381,"NA":1383},{"trials":1365,"activeCount":83},[],{"trials":1367,"activeCount":83},[],{"trials":1369,"activeCount":83},[1370],{"nctId":1371,"briefTitle":1372,"status":360,"phases":1373,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":1157,"conditions":1376,"interventions":1378},"NCT02994784","Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients",[73],"2022-07-01","2018-01-08",[1377],"Amyloidosis; Systemic",[1362],{"trials":1380,"activeCount":83},[],{"trials":1382,"activeCount":83},[],{"trials":1384,"activeCount":83},[],{"intervention":1386,"totalTrials":79,"cells":1387},"Topiramate",{"EARLY_PHASE1":1388,"PHASE1":1390,"PHASE2":1392,"PHASE3":1408,"PHASE4":1410,"NA":1412},{"trials":1389,"activeCount":83},[],{"trials":1391,"activeCount":83},[],{"trials":1393,"activeCount":83},[1394],{"nctId":1395,"briefTitle":1396,"status":360,"phases":1397,"primaryCompletion":794,"completion":794,"start":1398,"enrollment":1399,"conditions":1400,"interventions":1404},"NCT00862563","Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism",[73],"2009-05",85,[1401,1402,1403],"Alcoholism","Alcohol Dependence","Alcohol Abuse",[1386,1405,1406,1407],"Zonisamide","Levetiracetam","Sugar Pill",{"trials":1409,"activeCount":83},[],{"trials":1411,"activeCount":83},[],{"trials":1413,"activeCount":83},[],{"intervention":1405,"totalTrials":79,"cells":1415},{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1420,"PHASE3":1426,"PHASE4":1428,"NA":1430},{"trials":1417,"activeCount":83},[],{"trials":1419,"activeCount":83},[],{"trials":1421,"activeCount":83},[1422],{"nctId":1395,"briefTitle":1396,"status":360,"phases":1423,"primaryCompletion":794,"completion":794,"start":1398,"enrollment":1399,"conditions":1424,"interventions":1425},[73],[1401,1402,1403],[1386,1405,1406,1407],{"trials":1427,"activeCount":83},[],{"trials":1429,"activeCount":83},[],{"trials":1431,"activeCount":83},[],{"intervention":1406,"totalTrials":79,"cells":1433},{"EARLY_PHASE1":1434,"PHASE1":1436,"PHASE2":1438,"PHASE3":1444,"PHASE4":1446,"NA":1448},{"trials":1435,"activeCount":83},[],{"trials":1437,"activeCount":83},[],{"trials":1439,"activeCount":83},[1440],{"nctId":1395,"briefTitle":1396,"status":360,"phases":1441,"primaryCompletion":794,"completion":794,"start":1398,"enrollment":1399,"conditions":1442,"interventions":1443},[73],[1401,1402,1403],[1386,1405,1406,1407],{"trials":1445,"activeCount":83},[],{"trials":1447,"activeCount":83},[],{"trials":1449,"activeCount":83},[],{"intervention":1407,"totalTrials":79,"cells":1451},{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1456,"PHASE3":1462,"PHASE4":1464,"NA":1466},{"trials":1453,"activeCount":83},[],{"trials":1455,"activeCount":83},[],{"trials":1457,"activeCount":83},[1458],{"nctId":1395,"briefTitle":1396,"status":360,"phases":1459,"primaryCompletion":794,"completion":794,"start":1398,"enrollment":1399,"conditions":1460,"interventions":1461},[73],[1401,1402,1403],[1386,1405,1406,1407],{"trials":1463,"activeCount":83},[],{"trials":1465,"activeCount":83},[],{"trials":1467,"activeCount":83},[],{"intervention":1469,"totalTrials":79,"cells":1470},"Fecal microbiota transplant G3",{"EARLY_PHASE1":1471,"PHASE1":1473,"PHASE2":1475,"PHASE3":1485,"PHASE4":1487,"NA":1489},{"trials":1472,"activeCount":83},[],{"trials":1474,"activeCount":83},[],{"trials":1476,"activeCount":83},[1477],{"nctId":1478,"briefTitle":1479,"status":360,"phases":1480,"primaryCompletion":861,"completion":861,"start":1481,"enrollment":777,"conditions":1482,"interventions":1484},"NCT03795233","Fecal Microbiota Transplant for Primary CDI",[72,73],"2019-08-23",[1483],"Clostridium Difficile Infection",[1469],{"trials":1486,"activeCount":83},[],{"trials":1488,"activeCount":83},[],{"trials":1490,"activeCount":83},[],{"intervention":1492,"totalTrials":79,"cells":1493},"Panitumumab",{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1498,"PHASE3":1508,"PHASE4":1510,"NA":1512},{"trials":1495,"activeCount":83},[],{"trials":1497,"activeCount":83},[],{"trials":1499,"activeCount":83},[1500],{"nctId":1501,"briefTitle":1502,"status":632,"phases":1503,"primaryCompletion":1504,"completion":1504,"start":1504,"enrollment":83,"conditions":1505,"interventions":1507},"NCT01172717","Study of Panitumumab in the Treatment of Carcinoid Syndrome",[73],"2013-07",[1506],"Carcinoid Syndrome",[1492],{"trials":1509,"activeCount":83},[],{"trials":1511,"activeCount":83},[],{"trials":1513,"activeCount":83},[],{"intervention":770,"totalTrials":79,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1517,"activeCount":83},[],{"trials":1519,"activeCount":83},[],{"trials":1521,"activeCount":83},[1522],{"nctId":761,"briefTitle":762,"status":198,"phases":1523,"primaryCompletion":764,"completion":764,"start":765,"enrollment":766,"conditions":1524,"interventions":1525},[73],[26],[769,770,732],{"trials":1527,"activeCount":83},[],{"trials":1529,"activeCount":83},[],{"trials":1531,"activeCount":83},[],{"intervention":1533,"totalTrials":79,"cells":1534},"polyethylene glycol (PEG-ELS) and bisacodyl",{"EARLY_PHASE1":1535,"PHASE1":1537,"PHASE2":1539,"PHASE3":1550,"PHASE4":1552,"NA":1554},{"trials":1536,"activeCount":83},[],{"trials":1538,"activeCount":83},[],{"trials":1540,"activeCount":83},[1541],{"nctId":1542,"briefTitle":1543,"status":632,"phases":1544,"primaryCompletion":1545,"completion":1545,"start":1546,"enrollment":83,"conditions":1547,"interventions":1549},"NCT01044394","Same-day, Reduced Volume Bowel Preparation",[73],"2011-06","2010-01",[1548],"Bowel Preparation",[1533],{"trials":1551,"activeCount":83},[],{"trials":1553,"activeCount":83},[],{"trials":1555,"activeCount":83},[],{"intervention":1557,"totalTrials":79,"cells":1558},"BZD discontinuation protocol",{"EARLY_PHASE1":1559,"PHASE1":1561,"PHASE2":1563,"PHASE3":1573,"PHASE4":1575,"NA":1577},{"trials":1560,"activeCount":83},[],{"trials":1562,"activeCount":83},[],{"trials":1564,"activeCount":83},[1565],{"nctId":1566,"briefTitle":1567,"status":198,"phases":1568,"primaryCompletion":1569,"completion":1569,"start":1570,"enrollment":680,"conditions":1571,"interventions":1572},"NCT04109118","Benzodiazepine Discontinuation in Opioid Agonist Therapy",[73],"2021-07-08","2021-03-18",[412],[1557],{"trials":1574,"activeCount":83},[],{"trials":1576,"activeCount":83},[],{"trials":1578,"activeCount":83},[],{"intervention":1580,"totalTrials":79,"cells":1581},"Etoposide",{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1586,"PHASE3":1596,"PHASE4":1598,"NA":1600},{"trials":1583,"activeCount":83},[],{"trials":1585,"activeCount":83},[],{"trials":1587,"activeCount":83},[1588],{"nctId":1589,"briefTitle":1590,"status":360,"phases":1591,"primaryCompletion":1374,"completion":1374,"start":1592,"enrollment":24,"conditions":1593,"interventions":1595},"NCT04356690","Etoposide in Patients With COVID-19 Infection",[73],"2020-05-08",[1594],"COVID-19",[1580],{"trials":1597,"activeCount":83},[],{"trials":1599,"activeCount":83},[],{"trials":1601,"activeCount":83},[],{"intervention":1160,"totalTrials":79,"cells":1603},{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1608,"PHASE3":1614,"PHASE4":1616,"NA":1618},{"trials":1605,"activeCount":83},[],{"trials":1607,"activeCount":83},[],{"trials":1609,"activeCount":83},[1610],{"nctId":1151,"briefTitle":1152,"status":198,"phases":1611,"primaryCompletion":1154,"completion":1155,"start":1156,"enrollment":1157,"conditions":1612,"interventions":1613},[72,73],[813],[1160,801],{"trials":1615,"activeCount":83},[],{"trials":1617,"activeCount":83},[],{"trials":1619,"activeCount":83},[],{"intervention":1621,"totalTrials":79,"cells":1622},"Cordycepin",{"EARLY_PHASE1":1623,"PHASE1":1625,"PHASE2":1637,"PHASE3":1639,"PHASE4":1641,"NA":1643},{"trials":1624,"activeCount":83},[],{"trials":1626,"activeCount":83},[1627],{"nctId":1628,"briefTitle":1629,"status":198,"phases":1630,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":1634,"interventions":1635},"NCT00003005","Chemotherapy With Cordycepin Plus Pentostatin in Treating Patients With Refractory Acute Lymphocytic or Chronic Myelogenous Leukemia",[72],"2001-03","1997-12",14,[1217],[1621,1636],"Deoxycoformycin",{"trials":1638,"activeCount":83},[],{"trials":1640,"activeCount":83},[],{"trials":1642,"activeCount":83},[],{"trials":1644,"activeCount":83},[],{"intervention":1636,"totalTrials":79,"cells":1646},{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1655,"PHASE3":1657,"PHASE4":1659,"NA":1661},{"trials":1648,"activeCount":83},[],{"trials":1650,"activeCount":83},[1651],{"nctId":1628,"briefTitle":1629,"status":198,"phases":1652,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":1653,"interventions":1654},[72],[1217],[1621,1636],{"trials":1656,"activeCount":83},[],{"trials":1658,"activeCount":83},[],{"trials":1660,"activeCount":83},[],{"trials":1662,"activeCount":83},[],{"intervention":1664,"totalTrials":79,"cells":1665},"arginine butyrate",{"EARLY_PHASE1":1666,"PHASE1":1668,"PHASE2":1682,"PHASE3":1684,"PHASE4":1686,"NA":1688},{"trials":1667,"activeCount":83},[],{"trials":1669,"activeCount":83},[1670],{"nctId":1671,"briefTitle":1672,"status":198,"phases":1673,"primaryCompletion":1674,"completion":1674,"start":1675,"conditions":1676,"interventions":1680},"NCT00006340","Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus",[72],"2000-07","1994-12",[1217,1677,1678,1679],"Lymphoma","Precancerous Condition","Small Intestine Cancer",[1664,1681],"ganciclovir",{"trials":1683,"activeCount":83},[],{"trials":1685,"activeCount":83},[],{"trials":1687,"activeCount":83},[],{"trials":1689,"activeCount":83},[],{"intervention":1681,"totalTrials":79,"cells":1691},{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1700,"PHASE3":1702,"PHASE4":1704,"NA":1706},{"trials":1693,"activeCount":83},[],{"trials":1695,"activeCount":83},[1696],{"nctId":1671,"briefTitle":1672,"status":198,"phases":1697,"primaryCompletion":1674,"completion":1674,"start":1675,"conditions":1698,"interventions":1699},[72],[1217,1677,1678,1679],[1664,1681],{"trials":1701,"activeCount":83},[],{"trials":1703,"activeCount":83},[],{"trials":1705,"activeCount":83},[],{"trials":1707,"activeCount":83},[],{"intervention":1709,"totalTrials":79,"cells":1710},"Glutamine",{"EARLY_PHASE1":1711,"PHASE1":1713,"PHASE2":1724,"PHASE3":1726,"PHASE4":1728,"NA":1730},{"trials":1712,"activeCount":83},[],{"trials":1714,"activeCount":83},[1715],{"nctId":1716,"briefTitle":1717,"status":198,"phases":1718,"primaryCompletion":1719,"completion":1719,"start":1720,"enrollment":11,"conditions":1721,"interventions":1723},"NCT02351323","Novel Type 2 Diabetes Mellitus Preventive Therapies",[72],"2014-08","2010-05",[1722],"Diabetes",[1709],{"trials":1725,"activeCount":83},[],{"trials":1727,"activeCount":83},[],{"trials":1729,"activeCount":83},[],{"trials":1731,"activeCount":83},[],{"intervention":1733,"totalTrials":79,"cells":1734},"Lacosamide",{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1749,"PHASE3":1751,"PHASE4":1753,"NA":1755},{"trials":1736,"activeCount":83},[],{"trials":1738,"activeCount":83},[1739],{"nctId":1740,"briefTitle":1741,"status":198,"phases":1742,"primaryCompletion":1743,"completion":1743,"start":1744,"enrollment":1745,"conditions":1746,"interventions":1748},"NCT03271528","Lacosamide Effects on Alcohol Self Administration and Craving in Heavy Drinkers",[72],"2020-08-31","2018-04-15",66,[1747],"Alcohol Use Disorder",[1733],{"trials":1750,"activeCount":83},[],{"trials":1752,"activeCount":83},[],{"trials":1754,"activeCount":83},[],{"trials":1756,"activeCount":83},[],{"intervention":1758,"totalTrials":79,"cells":1759},"autologous tumor cell vaccine",{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1773,"PHASE3":1775,"PHASE4":1777,"NA":1779},{"trials":1761,"activeCount":83},[],{"trials":1763,"activeCount":83},[1764],{"nctId":1765,"briefTitle":1766,"status":360,"phases":1767,"primaryCompletion":1768,"completion":1768,"start":1769,"enrollment":19,"conditions":1770,"interventions":1771},"NCT00100971","Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia",[72],"2007-03","2004-04",[1217],[1758,1772],"therapeutic autologous dendritic cells",{"trials":1774,"activeCount":83},[],{"trials":1776,"activeCount":83},[],{"trials":1778,"activeCount":83},[],{"trials":1780,"activeCount":83},[],{"intervention":1772,"totalTrials":79,"cells":1782},{"EARLY_PHASE1":1783,"PHASE1":1785,"PHASE2":1791,"PHASE3":1793,"PHASE4":1795,"NA":1797},{"trials":1784,"activeCount":83},[],{"trials":1786,"activeCount":83},[1787],{"nctId":1765,"briefTitle":1766,"status":360,"phases":1788,"primaryCompletion":1768,"completion":1768,"start":1769,"enrollment":19,"conditions":1789,"interventions":1790},[72],[1217],[1758,1772],{"trials":1792,"activeCount":83},[],{"trials":1794,"activeCount":83},[],{"trials":1796,"activeCount":83},[],{"trials":1798,"activeCount":83},[],{"intervention":1800,"totalTrials":79,"cells":1801},"Pitolisant",{"EARLY_PHASE1":1802,"PHASE1":1804,"PHASE2":1815,"PHASE3":1817,"PHASE4":1819,"NA":1821},{"trials":1803,"activeCount":83},[],{"trials":1805,"activeCount":83},[1806],{"nctId":1807,"briefTitle":1808,"status":360,"phases":1809,"primaryCompletion":1810,"completion":1810,"start":1811,"enrollment":19,"conditions":1812,"interventions":1814},"NCT04596267","Pitolisant Effects on Alcohol Self-Administration in Heavy Drinkers",[72],"2023-02-03","2021-09-13",[1747,1813],"Alcohol Drinking",[1800],{"trials":1816,"activeCount":83},[],{"trials":1818,"activeCount":83},[],{"trials":1820,"activeCount":83},[],{"trials":1822,"activeCount":83},[],{"intervention":1824,"totalTrials":79,"cells":1825},"Exenatide",{"EARLY_PHASE1":1826,"PHASE1":1828,"PHASE2":1838,"PHASE3":1840,"PHASE4":1842,"NA":1844},{"trials":1827,"activeCount":83},[],{"trials":1829,"activeCount":83},[1830],{"nctId":1831,"briefTitle":1832,"status":360,"phases":1833,"primaryCompletion":1834,"completion":1834,"start":1835,"enrollment":24,"conditions":1836,"interventions":1837},"NCT03645408","The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers",[72],"2021-07-01","2019-05-02",[1747],[1824],{"trials":1839,"activeCount":83},[],{"trials":1841,"activeCount":83},[],{"trials":1843,"activeCount":83},[],{"trials":1845,"activeCount":83},[],{"intervention":1847,"totalTrials":79,"cells":1848},"Routine Nutritional Support plus supplemental IV amino acids",{"EARLY_PHASE1":1849,"PHASE1":1860,"PHASE2":1862,"PHASE3":1864,"PHASE4":1866,"NA":1868},{"trials":1850,"activeCount":83},[1851],{"nctId":1852,"briefTitle":1853,"status":198,"phases":1854,"primaryCompletion":1855,"completion":1855,"start":1856,"enrollment":203,"conditions":1857,"interventions":1859},"NCT02837861","Early and Adequate Protein Feeding Post-Traumatic Injury",[71],"2019-10-18","2017-03-07",[1858],"Protein Feeding in Post-traumatic Injury Patients",[1847],{"trials":1861,"activeCount":83},[],{"trials":1863,"activeCount":83},[],{"trials":1865,"activeCount":83},[],{"trials":1867,"activeCount":83},[],{"trials":1869,"activeCount":83},[],{"intervention":1871,"totalTrials":79,"cells":1872},"Povidone-Iodine",{"EARLY_PHASE1":1873,"PHASE1":1884,"PHASE2":1886,"PHASE3":1888,"PHASE4":1890,"NA":1892},{"trials":1874,"activeCount":83},[1875],{"nctId":1876,"briefTitle":1877,"status":632,"phases":1878,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":83,"conditions":1881,"interventions":1883},"NCT04457765","Betadine Effect on Nasal Mucosa Cilia",[71],"2022-09","2021-04",[1882],"Rhinoplasty",[1871],{"trials":1885,"activeCount":83},[],{"trials":1887,"activeCount":83},[],{"trials":1889,"activeCount":83},[],{"trials":1891,"activeCount":83},[],{"trials":1893,"activeCount":83},[],{"intervention":1895,"totalTrials":79,"cells":1896},"Glycolic acid peel alone",{"EARLY_PHASE1":1897,"PHASE1":1910,"PHASE2":1912,"PHASE3":1914,"PHASE4":1916,"NA":1918},{"trials":1898,"activeCount":83},[1899],{"nctId":1900,"briefTitle":1901,"status":632,"phases":1902,"primaryCompletion":1903,"completion":1904,"start":1905,"enrollment":83,"conditions":1906,"interventions":1908},"NCT02812719","Treatment of Melasma With Glycolic Acid-Salicylic Acid Peel Versus Glycolic Acid Peel",[71],"2018-12","2019-02","2018-07",[1907],"Melasma",[1895,1909],"Glycolic and salicylic acid peel",{"trials":1911,"activeCount":83},[],{"trials":1913,"activeCount":83},[],{"trials":1915,"activeCount":83},[],{"trials":1917,"activeCount":83},[],{"trials":1919,"activeCount":83},[],{"intervention":1909,"totalTrials":79,"cells":1921},{"EARLY_PHASE1":1922,"PHASE1":1928,"PHASE2":1930,"PHASE3":1932,"PHASE4":1934,"NA":1936},{"trials":1923,"activeCount":83},[1924],{"nctId":1900,"briefTitle":1901,"status":632,"phases":1925,"primaryCompletion":1903,"completion":1904,"start":1905,"enrollment":83,"conditions":1926,"interventions":1927},[71],[1907],[1895,1909],{"trials":1929,"activeCount":83},[],{"trials":1931,"activeCount":83},[],{"trials":1933,"activeCount":83},[],{"trials":1935,"activeCount":83},[],{"trials":1937,"activeCount":83},[],{"intervention":1939,"totalTrials":79,"cells":1940},"Anti-parasitic medications",{"EARLY_PHASE1":1941,"PHASE1":1943,"PHASE2":1945,"PHASE3":1947,"PHASE4":1949,"NA":1951},{"trials":1942,"activeCount":83},[],{"trials":1944,"activeCount":83},[],{"trials":1946,"activeCount":83},[],{"trials":1948,"activeCount":83},[],{"trials":1950,"activeCount":83},[],{"trials":1952,"activeCount":83},[1953],{"nctId":1954,"briefTitle":1955,"status":198,"phases":1956,"primaryCompletion":1957,"completion":1957,"start":1958,"enrollment":1959,"conditions":1960,"interventions":1963},"NCT03598842","Tuberculosis - Learning the Impact of Nutrition",[76],"2025-12-29","2019-07-12",786,[1961,254,1962],"Tuberculosis","Helminth Infection",[1939],{"intervention":1965,"totalTrials":79,"cells":1966},"Oral amoxicillin",{"EARLY_PHASE1":1967,"PHASE1":1969,"PHASE2":1971,"PHASE3":1973,"PHASE4":1975,"NA":1977},{"trials":1968,"activeCount":83},[],{"trials":1970,"activeCount":83},[],{"trials":1972,"activeCount":83},[],{"trials":1974,"activeCount":83},[],{"trials":1976,"activeCount":83},[],{"trials":1978,"activeCount":83},[1979],{"nctId":1980,"briefTitle":1981,"status":198,"phases":1982,"completion":302,"start":1983,"conditions":1984,"interventions":1986},"NCT00227331","Equivalency Of Oral Amoxicillin Vs Injectable Penicillin In Children With Severe Pneumonia",[76],"1998-01",[1985],"Pneumonia",[1965],{"intervention":1988,"totalTrials":79,"cells":1989},"Genetic and epigenetic analysis",{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":1996,"PHASE4":1998,"NA":2000},{"trials":1991,"activeCount":83},[],{"trials":1993,"activeCount":83},[],{"trials":1995,"activeCount":83},[],{"trials":1997,"activeCount":83},[],{"trials":1999,"activeCount":83},[],{"trials":2001,"activeCount":83},[2002],{"nctId":2003,"briefTitle":2004,"status":198,"phases":2005,"primaryCompletion":2006,"completion":2006,"start":2007,"enrollment":2008,"conditions":2009,"interventions":2013},"NCT03718104","MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study",[],"2024-05-08","2018-12-01",46,[2010,2011,2012,1747],"Opioid-use Disorder","Neonatal Abstinence Syndrome","Pregnancy, High Risk",[1988],{"intervention":2015,"totalTrials":79,"cells":2016},"Pneumococcal Pneumonia vaccine",{"EARLY_PHASE1":2017,"PHASE1":2019,"PHASE2":2021,"PHASE3":2023,"PHASE4":2025,"NA":2027},{"trials":2018,"activeCount":83},[],{"trials":2020,"activeCount":83},[],{"trials":2022,"activeCount":83},[],{"trials":2024,"activeCount":83},[],{"trials":2026,"activeCount":83},[],{"trials":2028,"activeCount":83},[2029],{"nctId":2030,"briefTitle":2031,"status":198,"phases":2032,"primaryCompletion":2033,"completion":2033,"start":2034,"enrollment":2035,"conditions":2036,"interventions":2037},"NCT03056924","Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab",[],"2019-01-15","2017-07-05",173,[587],[2015,2038,2039],"Influenza vaccine","Hepatitis B vaccine",{"intervention":2038,"totalTrials":79,"cells":2041},{"EARLY_PHASE1":2042,"PHASE1":2044,"PHASE2":2046,"PHASE3":2048,"PHASE4":2050,"NA":2052},{"trials":2043,"activeCount":83},[],{"trials":2045,"activeCount":83},[],{"trials":2047,"activeCount":83},[],{"trials":2049,"activeCount":83},[],{"trials":2051,"activeCount":83},[],{"trials":2053,"activeCount":83},[2054],{"nctId":2030,"briefTitle":2031,"status":198,"phases":2055,"primaryCompletion":2033,"completion":2033,"start":2034,"enrollment":2035,"conditions":2056,"interventions":2057},[],[587],[2015,2038,2039],{"intervention":2039,"totalTrials":79,"cells":2059},{"EARLY_PHASE1":2060,"PHASE1":2062,"PHASE2":2064,"PHASE3":2066,"PHASE4":2068,"NA":2070},{"trials":2061,"activeCount":83},[],{"trials":2063,"activeCount":83},[],{"trials":2065,"activeCount":83},[],{"trials":2067,"activeCount":83},[],{"trials":2069,"activeCount":83},[],{"trials":2071,"activeCount":83},[2072],{"nctId":2030,"briefTitle":2031,"status":198,"phases":2073,"primaryCompletion":2033,"completion":2033,"start":2034,"enrollment":2035,"conditions":2074,"interventions":2075},[],[587],[2015,2038,2039],{"intervention":2077,"totalTrials":79,"cells":2078},"Drotrecogin alfa activated",{"EARLY_PHASE1":2079,"PHASE1":2081,"PHASE2":2083,"PHASE3":2085,"PHASE4":2087,"NA":2089},{"trials":2080,"activeCount":83},[],{"trials":2082,"activeCount":83},[],{"trials":2084,"activeCount":83},[],{"trials":2086,"activeCount":83},[],{"trials":2088,"activeCount":83},[],{"trials":2090,"activeCount":83},[2091],{"nctId":2092,"briefTitle":2093,"status":198,"phases":2094,"primaryCompletion":2095,"start":2096,"enrollment":2097,"conditions":2098,"interventions":2100},"NCT02843685","Regression Discontinuity Design to Evaluate of Drotrecogin Alpha Effectiveness",[],"2005-12","2002-12",12492,[2099],"Sepsis",[2077]]